Original Article
Qingpeng ointment for the treatment of localized eczema in Chinese children: a multicenter, randomized controlled study
Yan Li, Wei Xu, Baoqi Yang, Hongqing Tian, Yiqun Duan, Xiangdong Wang, Xueyan Lu, Zhenzhen Ye, Mei Ju, Heng Gu, Jianping Zhao, Xing Chen, Yuhan Wang, Lingling Liu, Linfeng Li
Published 2017-06-15
Cite as Chin J Dermatol, 2017, 50(6): 412-416. DOI: 10.3760/cma.j.issn.0412-4030.2017.06.006
Abstract
ObjectiveTo evaluate the efficacy and safety of Qingpeng ointment for the treatment of localized eczema in children.
MethodsA multicenter, randomized, open-labeled, tacrolimus 0.03% ointment-controlled clinical trial was conducted. A total of 442 children with localized eczema were enrolled into this study, and divided into 2 groups to topically apply Qingpeng ointment (Qingpeng group) and tacrolimus 0.03% ointment (tacrolimus group) respectively twice a day for 2 weeks. The children were followed up before the treatment and 1, 2 weeks after the treatment, and the efficacy and safety were evaluated at the same time.
ResultsClinical data from 426 children were included in the efficacy analysis. At 1, 2 weeks after the treatment, there were no significant differences in the response rate between the Qingpeng group and tacrolimus group (1 week after the treatment: 78.92% vs. 81.77%, χ2= 0.545, P= 0.460; 2 weeks after the treatment: 98.65% vs. 97.54%, χ2= 0.721, P= 0.396) . However, the pruritus scores at 1, 2 weeks after the treatment were both significantly lower in the Qingpeng group than in the tacrolimus group (1 week: F= 14.001, P= 0.000; 2 weeks: F= 11.252, P= 0.001) . At 1 week after the treatment, the incidence rate of adverse reactions was significantly lower in the Qingpeng group than in the tacrolimus group (P < 0.05) . Mild itching, burning sensation and other local irritant sensations were the most common adverse reactions.
ConclusionQingpeng ointment is safe and effective for the treatment of localized eczema in children with good tolerability.
Key words:
Eczema; Child; Randomized controlled trials; Multicenter study; Qingpeng ointment
Contributor Information
Yan Li
Department of Dermatology and Venereology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China
Wei Xu
Department of Dermatology and Venereology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China
Baoqi Yang
Department of Dermatology, Shandong Provincial Institute of Dermatology and Venereology, Jinan 250022, China
Hongqing Tian
Department of Dermatology, Shandong Provincial Institute of Dermatology and Venereology, Jinan 250022, China
Yiqun Duan
Department of Dermatology, Wuhan No. 1 Hospital, Wuhan 430022, China
Xiangdong Wang
Department of Dermatology, Wuhan No. 1 Hospital, Wuhan 430022, China
Xueyan Lu
Department of Dermatology, Peking University Third Hospital, Beijing 100191, China
Zhenzhen Ye
Department of Dermatology, Peking University Third Hospital, Beijing 100191, China
Mei Ju
Department of Physical Therapy, Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing 210042, China
Heng Gu
Department of Physical Therapy, Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing 210042, China
Jianping Zhao
Department of Dermatology, Chinese People′s Armed Police Force, Zhejiang Corps Hospital, Jiaxing 314000, Zhejiang, China
Xing Chen
Department of Dermatology, Chinese People′s Armed Police Force, Zhejiang Corps Hospital, Jiaxing 314000, Zhejiang, China
Yuhan Wang
Department of Dermatology, Peking University First Hospital, Beijing 100034, China
Lingling Liu
Department of Dermatology, Peking University First Hospital, Beijing 100034, China
Linfeng Li
Department of Dermatology and Venereology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China
